RxDoctor Payments Data

David Parris, MD

Internal Medicine · North Hollywood, CANPI 1154403921

Payments from drug & device makers

$2,489in general payments, 2019–2025

Across 141 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$450
  • Novo Nordisk$291
  • Boehringer Ingelheim$233
  • GSK$189
  • AstraZeneca$184
  • Sunovion Pharmaceuticals Inc.$147
  • plus $995 from 29 others

What the payments were for

  • Food & beverage$2,489100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,489 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$30,021
Medicare patients
96
Services billed
390

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban58$41,557
OzempicSemaglutide28$23,627
MounjaroTirzepatide20$18,897
JardianceEmpagliflozin14$17,903
XareltoRivaroxaban11$11,815
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$11,380
RybelsusSemaglutide13$10,795
Diclofenac Sodium25$4,252
Levothyroxine Sodium137$4,053
Atorvastatin Calcium215$2,607
Memantine Hcl31$2,350
SynthroidLevothyroxine Sodium14$1,302
Losartan Potassium82$1,004
Albuterol Sulfate HfaAlbuterol Sulfate43$988
Rosuvastatin Calcium88$948

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$38$41,55758 claims
Novo NordiskOzempic, Rybelsus$291$34,42241 claims
Lilly USA, LLCMounjaro$71$18,89720 claims
Boehringer IngelheimJardiance$233$17,90314 claims
Johnson & JohnsonXarelto$11$11,81511 claims
GSKTrelegy Ellipta$189$11,38014 claims
AbbVieSynthroid$107$1,30214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in North Hollywood

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →